NYXH
Nyxoah Sets Sights High After Strong Q4 2025 Earnings
Nyxoah, a leading medical technology company, has made significant strides in its commercialization efforts following FDA approval for its groundbreaking Genio device. In the fourth quarter of 2025, the company achieved impressive milestones, solidifying its position as a key player in the hypoglossal nerve stimulation market. According to Olivier Taelman,